GLP-1 persistence: What semaglutide data reveals about patient behavior
As the new year begins, many patients refocus on weight management and long-term health goals. At...
As the new year begins, many patients refocus on weight management and long-term health goals. At...
Artificial intelligence is no longer something healthcare and life sciences teams are testing on...
Regulatory decision-making depends on evidence that reflects how medical products perform in...
Industry trends in ulcerative colitis research: a new path Ulcerative colitis is a chronic...
New research is challenging long-held assumptions about privacy-preserving record linkage (PPRL)....
Our team had a great time at HCIC connecting with healthcare marketers, digital teams and consumer...
Real-world evidence (RWE) studies often stall on the same friction points: defining the most...
Veterans Day invites us to look beyond branch and rank to the people and stories behind the...
Alzheimer’s disease burden and the current therapy pipeline Alzheimer’s disease remains the leading...
Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought...
On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Bridge demonstration, extending GLP-1 access to certain Medicare beneficiaries.